BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 38154821)

  • 1. Improved recognition of lung function decline as signal of cystic fibrosis pulmonary exacerbation: a Cystic Fibrosis Learning Network Innovation Laboratory quality improvement initiative.
    List R; Solomon G; Bichl S; Horton BJ; Shen S; Corcoran B; Sadeghi H; Britto MT; Ren C; Albon D;
    BMJ Open Qual; 2023 Dec; 12(4):. PubMed ID: 38154821
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adjunctive Systemic Corticosteroids for Pulmonary Exacerbations of Cystic Fibrosis.
    McElvaney OJ; Heltshe SL; Odem-Davis K; West NE; Sanders DB; Fogarty B; VanDevanter DR; Flume PA; Goss CH
    Ann Am Thorac Soc; 2024 May; 21(5):716-726. PubMed ID: 38096105
    [No Abstract]   [Full Text] [Related]  

  • 3. [Chinese experts consensus statement: diagnosis and treatment of cystic fibrosis (2023)].
    ; ;
    Zhonghua Jie He He Hu Xi Za Zhi; 2023 Apr; 46(4):352-372. PubMed ID: 36990700
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants (most commonly F508del).
    Heneghan M; Southern KW; Murphy J; Sinha IP; Nevitt SJ
    Cochrane Database Syst Rev; 2023 Nov; 11(11):CD010966. PubMed ID: 37983082
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants (most commonly F508del).
    Southern KW; Murphy J; Sinha IP; Nevitt SJ
    Cochrane Database Syst Rev; 2020 Dec; 12(12):CD010966. PubMed ID: 33331662
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rationale and design of a randomized trial of home electronic symptom and lung function monitoring to detect cystic fibrosis pulmonary exacerbations: the early intervention in cystic fibrosis exacerbation (eICE) trial.
    Lechtzin N; West N; Allgood S; Wilhelm E; Khan U; Mayer-Hamblett N; Aitken ML; Ramsey BW; Boyle MP; Mogayzel PJ; Goss CH
    Contemp Clin Trials; 2013 Nov; 36(2):460-9. PubMed ID: 24055998
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cystic fibrosis learning network telehealth innovation lab during the COVID-19 pandemic: a success QI story for interdisciplinary care and agenda setting.
    Albon D; Thomas L; Hoberg L; Stamper S; Somerville L; Varghese P; Balasa E; Roman M; Britto MT; Miner M; Gehring E; Gammon C; Amin RS; Seid M; Powers M;
    BMJ Open Qual; 2022 May; 11(2):. PubMed ID: 35589277
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Changes in Care during the COVID-19 Pandemic for People with Cystic Fibrosis.
    Sanders DB; Wu R; O'Neil T; Elbert A; Petren K; Jain R; Ren CL
    Ann Am Thorac Soc; 2022 Oct; 19(10):1697-1703. PubMed ID: 35143374
    [No Abstract]   [Full Text] [Related]  

  • 9. Evaluating FEV1 decline in diagnosis and management of pulmonary exacerbations in children with cystic fibrosis.
    Bouzek DC; Ren CL; Thompson M; Slaven JE; Sanders DB
    Pediatr Pulmonol; 2022 Jul; 57(7):1709-1716. PubMed ID: 35429154
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association Between Number of Intravenous Antipseudomonal Antibiotics and Clinical Outcomes of Pediatric Cystic Fibrosis Pulmonary Exacerbations.
    Cogen JD; Faino AV; Onchiri F; Hoffman LR; Kronman MP; Nichols DP; Rosenfeld M; Gibson RL
    Clin Infect Dis; 2021 Nov; 73(9):1589-1596. PubMed ID: 34100912
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Implementation of standardized cystic fibrosis care algorithm to improve the center data-quality improvement project international collaboration.
    Gokdemir Y; Eralp EE; Ergenekon AP; Yilmaz Yegit C; Yanaz M; Mursaloğlu H; Uzunoglu B; Kocamaz D; Tastan G; Kenis Coskun O; Filbrun A; Enochs C; Bouma S; Iwanicki C; Karakoc F; Nasr SZ; Karadag B
    J Cyst Fibros; 2023 Jul; 22(4):710-714. PubMed ID: 37037703
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pulmonary exacerbations and clinical outcomes in a longitudinal cohort of infants and preschool children with cystic fibrosis.
    Hoppe JE; Wagner BD; Sagel SD; Accurso FJ; Zemanick ET
    BMC Pulm Med; 2017 Dec; 17(1):188. PubMed ID: 29228933
    [TBL] [Abstract][Full Text] [Related]  

  • 13. BEAT CF pulmonary exacerbations core protocol for evaluating the management of pulmonary exacerbations in people with cystic fibrosis.
    Schultz A; McLeod C; Berry S; Marsh J; McKenzie A; Messer M; Wood J; Saville B; Jaffe A; Ranganathan S; Stick S; Wark P; Webb S; Snelling T
    Trials; 2023 Mar; 24(1):211. PubMed ID: 36949472
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Systemic Corticosteroids in the Management of Pediatric Cystic Fibrosis Pulmonary Exacerbations.
    Davis CS; Faino AV; Onchiri F; Gibson RL; Merjaneh L; Ramsey BW; Rosenfeld M; Cogen JD
    Ann Am Thorac Soc; 2023 Jan; 20(1):75-82. PubMed ID: 36044723
    [No Abstract]   [Full Text] [Related]  

  • 15. Preliminary method for profiling volatile organic compounds in breath that correlate with pulmonary function and other clinical traits of subjects diagnosed with cystic fibrosis: a pilot study.
    Woollam M; Siegel AP; Grocki P; Saunders JL; Sanders DB; Agarwal M; Davis MD
    J Breath Res; 2022 Feb; 16(2):. PubMed ID: 35120338
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Standard technical specifications for methacholine chloride (Methacholine) bronchial challenge test (2023)].
    ; ;
    Zhonghua Jie He He Hu Xi Za Zhi; 2024 Feb; 47(2):101-119. PubMed ID: 38309959
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potentiators (specific therapies for class III and IV mutations) for cystic fibrosis.
    Skilton M; Krishan A; Patel S; Sinha IP; Southern KW
    Cochrane Database Syst Rev; 2019 Jan; 1(1):CD009841. PubMed ID: 30616300
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sweat metabolomics before and after intravenous antibiotics for pulmonary exacerbation in people with cystic fibrosis.
    Woodley FW; Gecili E; Szczesniak RD; Shrestha CL; Nemastil CJ; Kopp BT; Hayes D
    Respir Med; 2022 Jan; 191():106687. PubMed ID: 34864373
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Routine spirometry in cystic fibrosis patients: impact on pulmonary exacerbation diagnosis and FEV1 decline.
    Aquino CSB; Rodrigues JC; Silva-Filho LVRFD
    J Bras Pneumol; 2022; 48(3):e20210237. PubMed ID: 35674545
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predicting return of lung function after a pulmonary exacerbation using the cystic fibrosis respiratory symptom diary-chronic respiratory infection symptom scale.
    Gill ER; Goss CH; Sagel SD; Wright ML; Horner SD; Zuñiga JA
    Res Sq; 2023 Sep; ():. PubMed ID: 37790510
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.